

Correspondence

Characterization of Immune Failure by Monocyte Activation Phenotypes in HIV-Infected Patients Receiving Antiretroviral Therapy

TO THE EDITOR—Wilson et al [1] demonstrated that, in human immunodeficiency virus (HIV)-infected subjects, levels of inflammatory biomarkers known to be associated with increased clinical risk (interleukin 6, D-dimer, high sensitive reactive-C protein, soluble CD14, and soluble CD163) are more closely related to markers of monocyte activation and migration than to markers of T-cell activation. These data suggest that monocytes may play a prominent role in chronic and serious non-AIDS events, such as premature cardiovascular disease and cancer. Meanwhile, several large cohort studies have demonstrated that HIV-infected subjects who do not undergo full CD4⁺ T-cell restoration during antiretroviral therapy (ART) (ie, those with immune failure [IF]) are at greater risk of developing these non-AIDS conditions [2–6].

Based on the findings of Wilson et al [1], we investigated monocyte activation phenotypes in a group of patients with IF, compared with patients who did obtain full CD4⁺ T-cell recovery with therapy (immune success [IS]). We performed a cross-sectional study in 84 HIV-infected subjects with current CD4⁺ T-cell counts <350/μL (IF; n = 39) or >500/μL (IS; n = 45) after ≥18 months of ART and with HIV RNA levels <50 copies/mL for ≥12 months. Peripheral monocyte/macrophage (M/M) phenotypes (based on CD14 and CD16 surface expression in classic CD14⁺⁺CD16⁻, intermediate CD14⁺⁺CD16⁺, and non-classic CD14⁺CD16⁺⁺ monocytes) as well as specific surface activation markers (eg, CD163 and CD11b) were evaluated by flow cytometry on fresh samples.

Patient demographic characteristics and immunological findings are provided in Table 1. The 2 groups were matched by both age and CD4⁺ T-cell nadir. The IF and IS patient groups did not significantly differ by sex, duration of HIV infection, modality of transmission for HIV infection, Centers for Disease Control and Prevention stage, length of ART, or hepatitis B virus infection. The prevalence of hepatitis C virus infection was higher in patients with IF than in those with IS (38.5% vs 17.8%, respectively; $P < .05$). By definition, patients with IF displayed lower CD4⁺ T-cell counts (median [interquartile range (IQR)] for IF vs IS, 268 [218–314] vs 663 [550–850] cells/μL; $P < .05$). A developmental relationship between circulating monocyte subsets (from classic by intermediate to nonclassic) might be postulated. During systemic infection and under proinflammatory stimuli, there is an increase first of the intermediate cells followed by the nonclassic CD14⁺CD16⁺⁺ monocytes [7].

We found that, compared with patients with IS, those with IF showed lower levels of classic and higher levels of intermediate monocytes (CD14⁺⁺CD16⁻, 82.5% of total CD14⁺ [IQR, 77.0%–86.5%] for IF vs 84.5% [79.8%–88.3%] for IS [$P = .05$]; CD14⁺⁺CD16⁺, 4.6% of total CD14⁺ [3.2%–6.2%] vs 4.0% [2.5%–5.1%] [$P = .04$]). Proportions of nonclassic monocytes were also higher in patients with IF, although this difference did not reach statistical significance (CD14⁺CD16⁺⁺, 6.7% of total CD14⁺ [4.5%–9.6%] for IF vs 5.6% [3.3%–9.0%] for IS).

CD163 is a haptoglobin-hemoglobin scavenger receptor expressed by monocytes and macrophages, cleaved from the cell by proinflammatory stimuli and involved as soluble receptor (soluble CD163) in the regulation of inflammation [8]. Patients

with IF displayed lower expression of CD163 than those with IS, for both total and classic monocytes (CD14⁺CD163⁺, 89.1% of total CD14⁺ [IQR, 85.8%–91.9%] for IF vs 92.5% [88.3%–93.8%] for IS [$P = .02$]; CD14⁺⁺CD16⁻CD163⁺, 79.9% of CD14⁺⁺CD16⁻ [74.0%–83.2%] vs 83.7% [78.9%–86.9%] [$P = .01$]). Although the values were higher in patients with IF, we found no significant differences between the 2 groups in the proportions of CD14⁺⁺CD16⁺CD163⁺ (4.3% of CD14⁺⁺CD16⁺ [IQR, 3.0%–6.2%] for IF vs 3.9% [2.5%–5.1%] for IS; $P = .07$) or CD14⁺CD16⁺⁺CD163⁺ monocytes (1.9% of CD14⁺CD16⁺⁺ [0.9%–2.6%] vs 1.2% [0.6%–2.5%]; $P = .35$).

CD11b (Mac-1), a member of the β2-integrin family, is involved in monocyte adhesion and endothelial transmigration as well as in macrophage activation. Constitutively present at low levels on the cell surface, its expression is increased after proinflammatory stimulation with cytokines (interleukin 1, tumor necrosis factor, and interferon γ) and lipopolysaccharide [9]. The frequency of CD14⁺CD11b⁺ did not differ substantially between the 2 groups (median, 98.1% of total CD14⁺ [IQR, 96.8%–99.1%] for IF vs 97.8% [95.8%–98.8%] for IS; $P = .40$). In contrast, patients with IF showed lower proportions of CD14⁺⁺CD16⁻CD11b⁺ (82.5% of CD14⁺⁺CD16⁻ [IQR, 77.0%–86.5%] for IF vs 84.5% [79.8%–88.3%] for IS; $P < .05$) and higher proportions of CD14⁺⁺CD16⁺CD11b⁺ (4.6% of CD14⁺⁺CD16⁺ [3.2%–6.2%] vs 4.0% [2.5%–5.1%]; $P < .05$) monocytes. Levels of non-classic CD14⁺CD16⁺⁺ monocytes expressing CD11b⁺ did not differ significantly between the 2 groups (6.2% of CD14⁺CD16⁺⁺ [IQR, 4.3%–8.9%] for IF vs 4.3% [2.9%–8.1%] for IS; $P = .08$). Moreover, we found no differences in the expression of HLA-DR,

Table 1. Epidemiological and Viroimmunological Data and Markers of Monocyte Activation^a

Data and Markers	Immune Failure (n = 39)	Immune Success (n = 45)	P Value ^b
Epidemiological and viroimmunological data			
Age, y	51 (46–54.4)	48 (45–52)	NS
Male sex, No. (%)	33 (84.6)	38 (84.4)	NS
Previous AIDS diagnosis, No. (%)	31 (79.5)	35 (77.8)	NS
Duration of HIV infection, y	9 (4–20)	11 (6–21)	NS
CD4 ⁺ T-cell nadir, cells/μL	49 (18–113)	87 (39–162)	NS
Duration of ART	6 (3–16)	9 (5–16)	NS
HCV positive, No. (%)	15 (38.5)	8 (17.8)	<.05
HBsAg positive, No. (%)	5 (12.8)	4 (8.9)	NS
Current CD4 ⁺ T-cell count, cells/μL	268 (218–314)	663 (555–850)	<.05
Current CD4 ⁺ T-cell proportion, %	17 (13–22)	29 (26–34)	<.05
Current CD4/CD8 ratio	0.36 (0.26–0.49)	0.76 (0.60–0.92)	<.05
Markers of monocyte activation			
CD14 ⁺ , %	6.24 (4.70–7.59)	6.12 (4.65–7.04)	NS
CD14 ⁺⁺ CD16 ⁻ , % CD14 ⁺	82.50 (77.00–86.55)	84.54 (79.76–88.33)	.05
CD14 ⁺⁺ CD16 ⁺ , % CD14 ⁺	4.61 (3.23–6.20)	4.03 (2.51–5.06)	.04
CD14 ⁺ CD16 ⁺⁺ , % CD14 ⁺	6.75 (4.49–9.60)	5.62 (3.31–9.02)	NS
CD14 ⁺ CD163 ⁺ , % CD14 ⁺	89.08 (85.78–91.93)	92.46 (88.32–93.77)	.02
CD14 ⁺⁺ CD16 ⁻ CD163 ⁺ , % CD14 ⁺⁺ CD16 ⁻	79.88 (74.03–83.22)	83.66 (78.99–86.86)	.01
CD14 ⁺⁺ CD16 ⁺ CD163 ⁺ , % CD14 ⁺⁺ CD16 ⁺	4.26 (3.02–6.16)	3.91 (2.51–5.06)	NS
CD14 ⁺ CD16 ⁺⁺ CD163 ⁺ , % CD14 ⁺ CD16 ⁺⁺	1.88 (0.86–2.61)	1.19 (0.62–2.46)	NS
CD14 ⁺ CD11b ⁺ , % CD14 ⁺	98.08 (96.84–99.06)	97.77 (95.77–98.85)	NS
CD14 ⁺⁺ CD16 ⁻ CD11b ⁺ , % CD14 ⁺⁺ CD16 ⁻	82.50 (76.98–86.55)	84.54 (79.76–88.33)	<.05
CD14 ⁺⁺ CD16 ⁺ CD11b ⁺ , % CD14 ⁺⁺ CD16 ⁺	4.61 (3.23–6.20)	4.03 (2.51–5.06)	<.05
CD14 ⁺ CD16 ⁺⁺ CD11b ⁺ , % CD14 ⁺ CD16 ⁺⁺	6.21 (4.30–8.95)	4.35 (2.86–8.06)	NS
CD14 ⁺ HLADR ⁺ , % CD14 ⁺	93.98 (89.38–96.21)	93.30 (91.37–96.23)	NS
CD14 ⁺ CD38 ⁺ , % CD14 ⁺	98.37 (97.07–99.11)	98.44 (97.11–99.13)	NS
CD14 ⁺ CD69 ⁺ , % CD14 ⁺	32.98 (20.27–50.12)	37.31 (22.26–58.28)	NS

Abbreviations: ART, antiretroviral therapy; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HIV, human immunodeficiency virus; NS, not significant ($P > .05$).

^a Unless identified as No. (%), data represent median (interquartile range) values.

^b Statistical analyses were performed using Wilcoxon and χ^2 tests.

CD38, or CD69 on M/M between the 2 groups.

We found that suboptimal CD4⁺ T-cell recovery during ART in patients with IF is associated with a shift of M/M phenotype from classic toward intermediate and nonclassic subsets, suggesting a role of these cells in the systemic immune activation typically observed in this group of patients.

The differential expression of CD163 and CD11b on monocytes observed in IF compared with IS could suggest a greater effort by the immune system to deal with this proinflammatory condition. Our findings provide further evidence that innate immune activation contributes to the

pathogenesis of inflammation and poor CD4⁺ T-cell restoration. Studies focusing on relationship between monocyte activation phenotypes and clinical end points (serious non-AIDS conditions) are indicated to evaluate the prognostic role of these cellular markers and potential strategies targeting persistent inflammation in the context of viral suppression.

Notes

Financial support. This work was supported by the Gilead Fellowship Program 2011 and An-laidis Lombardia.

Potential conflicts of interest. All authors: No potential conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Alessandra Bandera,¹ Davide Mangioni,¹ Arianna Incontri,² Paolo Perseghin,² and Andrea Gori¹

¹Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milan-Bicocca, and ²Apheresis Unit Aferesi e Nuove Tecnologie Trasfusionali—Transfusion Medicine Service, San Gerardo Hospital, Monza, Italy

References

- Wilson EM, Singh A, Hullsiek KH, et al., Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) Investigators. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. *J Infect Dis* 2014; 210:1396–406.

2. Achhra AC, Amin J, Law MG, et al.; INSIGHT ESPRIT & SILCAAT study groups. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. *AIDS* **2010**; *24*:1877–86.
3. Baker JV, Peng G, Rapkin J, et al.; Terry Bein Community Programs for Clinical Research on AIDS (CPCRA). Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. *J Acquir Immune Defic Syndr* **2008**; *48*:541–6.
4. Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study. *J Acquir Immune Defic Syndr* **2010**; *55*:117–27.
5. Lapadula G, Cozzi-Lepri A, Marchetti G, et al.; ICONA Foundation Study. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment. *AIDS* **2013**; *27*:769–79.
6. Zoufaly A, Cozzi-Lepri A, Reekie J, et al.; EuroSIDA in EuroCoord. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. *PLoS One* **2014**; *9*:e87160.
7. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in Blood. *Blood* **2010**; *116*:e74–80.
8. Schaer DJ, Alayash AI, Buehler PW. Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD163, a scavenger receptor. *Antioxid Redox Signal* **2007**; *9*:991–9.
9. Lichte P, Grigoleit JS, Steiner EM, et al. Low dose LPS does not increase TLR4 expression on monocytes in a human in vivo model. *Cytokine* **2013**; *63*:74–80.

Received 4 February 2015; accepted 23 February 2015; electronically published 19 March 2015.

Correspondence: Alessandra Bandera, MD, PhD, Division of Infectious Diseases, Department of Internal Medicine, San Gerardo Hospital, University of Milano-Bicocca, Via Pergolesi 33, 20900 Monza, Italy (a.bandera@hsgerardo.org).

The Journal of Infectious Diseases® 2015;212:839–41

© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
DOI: 10.1093/infdis/jiv166